If HIF-1α is the cause of impaired glycolytic activity and therefore immune deficiency in HHT patients, then enhancing HIF will lead to improved energy metabolism and potentially an improved immune response in HHT patients. This evidence concerns the gene HIF1A and hereditary hemorrhagic telangiectasia.